000207845 001__ 207845
000207845 005__ 20230219174710.0
000207845 0247_ $$2CORDIS$$aG:(EU-Grant)768260$$d768260
000207845 0247_ $$2CORDIS$$aG:(EU-Call)H2020-SMEINST-2-2016-2017$$dH2020-SMEINST-2-2016-2017
000207845 0247_ $$2originalID$$acorda__h2020::768260
000207845 035__ $$aG:(EU-Grant)768260
000207845 150__ $$aContinuous Diaphragm Monitoring of mechanically ventilated patients$$y2017-08-01 - 2020-03-31
000207845 371__ $$aRESPINOR AS$$bRESPINOR AS$$dNorway$$ehttp://www.respinor.com$$vCORDIS
000207845 372__ $$aH2020-SMEINST-2-2016-2017$$s2017-08-01$$t2020-03-31
000207845 450__ $$aDiaMon$$wd$$y2017-08-01 - 2020-03-31
000207845 5101_ $$0I:(DE-588b)5098525-5$$2CORDIS$$aEuropean Union
000207845 680__ $$aRespinor aims to seize a major market opportunity through the clinical validation, technology maturation and commercialization of a unique ultrasound technology for Diaphragm Monitoring – DiaMon. DiaMon is a non-invasive ultrasound device that is designed to provide precise, continuous and real-time information of diaphragm function. The diaphragm is the main muscle involved in breathing.

Treatment with Mechanical Ventilation (MV) results in high costs for healthcare systems. The incremental cost of MV is estimated to be €1,500 per patient per day. With an estimated 1.35 million MV patients in the EU per year for an average of 4-5 days, this represents an expenditure of at least €8.1 billion annually. Therefore, it is highly important both clinically and economically to bring patients off MV and back to normal, spontaneous breathing as quickly as possible. 

There is currently a severe lack of accurate and cost-effective solutions to support the MV process. Respinor aims to fill this gap, by demonstrating and commercializing a cost-effective and user friendly ultrasound device, being the only effective non-invasive alternative to invasive catheter based solutions.

Under Eurostars and Horizon 2020 SME Phase 1 grants, Respinor has developed a first version of DiaMon and initiated clinical studies. Preliminary results are very promising. The overall objective of H2020 Phase 2 is to: 1. Demonstrate in large clinical trials (700 patients) that DiaMon can reduce MV failure compared with standard of care and 2. Further develop DiaMon into a commercial product with high usability and acceptance in the ICU setting. 

The accomplishment of the proposed project objectives will bring major benefits to Respinor with a forecast significant cumulated turnover by 2025 in the ICU MV market segment. The demonstration of the benefits of DiaMon in the weaving process will foster the entrance in the large respiratory market.
000207845 909CO $$ooai:juser.fz-juelich.de:839725$$pauthority$$pauthority:GRANT
000207845 909CO $$ooai:juser.fz-juelich.de:839725
000207845 970__ $$aoai:dnet:corda__h2020::90aed44e6acb4d2a78b4f219646fbbf3
000207845 980__ $$aG
000207845 980__ $$aCORDIS
000207845 980__ $$aAUTHORITY